Benign Paroxysmal Positional Vertigo
Conditions
Keywords
Benign paroxysmal positional vertigo, Vitamin D, Calcium, Prevention
Brief summary
The purpose of this study is to determine whether the supplementation of vitamin D and calcium prevents recurrences of benign paroxysmal positional vertigo in patients with vitamin D deficiency/insufficiency.
Interventions
DRUG400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate
The patients allocated to the intervention group will have a test for serum vitamin D, and receive 800 IU of vitamin D and 1000 mg of calcium as calcium carbonate when the serum vitamin D is decreased. The patients in the control group will be followed up without intervention for one year.
Sponsors
Ministry of Food and Drug Safety, Korea
Seoul National University Bundang Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age 18 years or older * brief episodes of vertigo induced by head motion * a typical positioning nystagmus characteristic of BPPV * no supplementation of vitamin D or calcium at the time of recruitment * informed consent to participate in this study * subject treated by repositioning maneuver
Exclusion criteria
* other identifiable disorders of the central nervous system * supplementation of vitamin D or calcium at the time of recruitment * pregnancy * a history of an allergic reaction, or a medically significant adverse reaction to the investigational product * contraindication to cholecalciferol and calcium carbonate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence frequency of benign paroxysmal positional vertigo | Up to 1 year | The intervention group will receive tablets containing 400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate twice daily (CAVID CHEWABLE TAB, Takeda Pharmaceuticals) for 12 months when the initial serum vitamin D is decreased. The compliance will be determined by the percentage of consumed tablets from the delivered tablets during the follow-up period. Discontinuation of the supplementation due to adverse effects or other reasons will be registered using the telephone interview together with the primary outcome date. Participants in the control group will not have any intervention or placebo. They will not be allowed to take vitamin D or calcium as supplements during the follow-up. The primary outcome measure is the recurrence of BPPV after one year. Data on recurrences will be collected using a monthly telephone interview, and the patients will be asked to visit the clinic whenever they have the symptoms of BPPV. All the recurrences of BPPV will be included. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in serum 25-hydroxy vitamin D level | Up to 1 year | In intervention group, the baseline vitamin D status of participants will be checked. And the level of 25-hydroxyvitamin D level will be rechecked at 2 months from the recruitment and at the end of the follow-up. |
| Falling frequency | Up to year | To determine the supplementation of the vitamin D and calcium carbonate is effective to decrease falling frequency. |
| Fracture frequency | Up to 1 year | To determine the supplementation of the vitamin D and calcium carbonate is effective to decrease fracture frequency. |
| Quality of life | Up to 1 year | To determine the supplementation of the vitamin D and calcium carbonate is related to quality of life using UCLA-dizziness questionnaire |
| Recurrence rate of benign paroxysmal positional vertigo | Up to 1 year | The intervention group will receive tablets containing 400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate twice daily (CAVID CHEWABLE TAB, Takeda Pharmaceuticals) for 12 months when the initial serum vitamin D is decreased. The compliance will be determined by the percentage of consumed tablets from the delivered tablets during the follow-up period. Discontinuation of the supplementation due to adverse effects or other reasons will be registered using the telephone interview together with the primary outcome date. Participants in the control group will not have any intervention or placebo. They will not be allowed to take vitamin D or calcium as supplements during the follow-up. The primary outcome measure is the recurrence rate of BPPV after one year. Data on recurrences will be collected using a monthly telephone interview, and the patients will be asked to visit the clinic whenever they have the symptoms of BPPV. All the recurrences of BPPV will be included. |
Countries
South Korea
Outcome results
None listed